



Odds of using Cord Blood

Traditional Stem Cell Transplants

- Umbilical Cord Blood (UCB) is an accepted source of hematopoietic stem cells (HSCs) that is equivalent to those found in the bone marrow.
- UCB stem cells have been used in stem cell transplants to treat hematological diseases and cancers since 1988. To date, there have been **>35,000** cord blood transplants worldwide.¹
- Probability of finding a match for patients in need of an HSC transplant depends on race/ethnicity.²
- Probability of finding an optimal adult bone marrow donor (high resolution match at HLA-A/HLA-B HLA-C and HLA-DRB1):²
 - Highest probability: 75% for whites of European descent
 - Lowest probability: 16% for blacks of South or Central American descent
- The cumulative probability that a person will have some type of stem cell transplant by age of 70 is approximately **1 in 200**.³
- In U.S., odds of:
 - A child using his/her own (autologous) cord blood: 1:5,0004
 - A child using donor (allogeneic) cord blood: 1:2,500⁴
- Parent's Guide to Cord Blood Foundation's confidential survey finds that the world inventory of cord blood in family banks is over 4 million as of the end of 2014.⁵
- World inventory of cord blood in public banks is over 630,000.6

Emerging Cell Therapies

The application of cord blood in regenerative medicine is currently under investigation for a variety of indications including cerebral palsy, autism, stroke, hypoplastic left heart syndrome, hypoxic ischemic encephalopathy (HIE), and acquired hearing loss. These trials are at an early stage. The possible benefit(s) of cord blood for these indications will become available once the clinical trials are completed.

Why do parents bank?

Once parents understand all of the benefits of storing their baby's cord blood, there are two options: public donation or family banking. Many parents struggle with this decision, unsure whether or not family banking is worth the cost. The best decision is an educated one. Parents should understand that cord blood stem cells can be used TODAY for a long list of treatments but as stem cell therapy advances...they may hold bigger PROMISE FOR TOMORROW



Table 1 - Emerging Therapies where children use their own Cord Blood

| DIAGNOSIS | TRIAL SITE | PHASE | NO. PATIENTS | ANTICIPATED TRIAL COMPLETION | TRIAL ID |
|------------------------------------|-----------------------------------|-------|--------------|---------------------------------|-------------|
| Cerebral palsy | Duke (USA) | 2 | 120 | Jan 2016 | NCT01147653 |
| | Texas Health Science Center (USA) | 2 | 30 | May 2017 | NCT01988584 |
| | Georgia Regents (USA) | 2 | 40 | Mar 2015 | NCT01072370 |
| Autism | Duke (USA) | 1 | 20 | Jul 2015 | NCT02176317 |
| | Sutter Health (USA) | 2 | 30 | Apr 2015 | NCT01638819 |
| Neonatal oxygen deprivation | Duke (USA) | 1 | 25 | Jun 2015 | NCT00593242 |
| | Singapore | 1 | 10 | Sep 2015 | NCT01649648 |
| | Japan | 1 | 6 | Feb 2018 | NCT02256618 |
| Hypoplastic left heart syndrome | Duke (USA) | 1 | 20 | Sep 2015 | NCT01445041 |
| | Mayo Clinic (USA) | 1 | 10 | Dec 2016 | NCT01883076 |
| Acquired hearing loss | Florida (USA) | 2 | 10 | Jan 2016 | NCT02038972 |
| Complications in preterm neonates | Poland | 1 | 40 | Dec 2015 | NCT02050971 |
| Type 1 diabetes | Germany | 1 | 18 | Sep 2014 | NCT00989547 |

Table 2 - Emerging Therapies using donated Cord Blood

| DIAGNOSIS | TRIAL SITE | PHASE | NO. PATIENTS | ANTICIPATED TRIAL COMPLETION | TRIAL ID |
|---|-----------------|-------|--------------|---------------------------------|-------------|
| Cerebral palsy | Korea | 2 | 120 | Jul 2015 | NCT01991145 |
| | Korea | 1 | 18 | Dec 2015 | NCT02025972 |
| Ischemic stroke | Duke (USA) | 1 | 10 | Aug 2017 | NCT02397018 |
| | Korea | 1 | 5 | Dec 2015 | NCT01884155 |
| | Hong Kong | 1 | 12 | Jul 2017 | NCT01673932 |
| Global developmental delay | Korea | 1 | 12 | Dec 2014 | NCT01769716 |
| Brain injury/neurode- generative disorders | Korea | 1 | 10 | Jul 2016 | NCT02236065 |
| Acquired brain injury | Korea | 1 | 3 | Dec 2014 | NCT01885663 |
| Epidermolysis bullosa | Minnesota (USA) | 2 | 75 | Oct 2019 | NCT01033552 |

REFERENCES FOR BODY OF PAGE

 Aldenhoven and Kurtzberg, Cytotherapy 2015; 17:765-774 Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future of directions;

clinical outcomes and future directions. 2. Gragert et al., NEJM 2014; 371:339-348 HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry.

Stem-Cell Grafts in the U.S. Registry. 3. Nietfeld, JJ et al., Biol. Blood and Marrow Trans. 2008; 14:316-322. 4. http://parentsguidecordblood.org/odds.php 5. http://parentsguidecordblood.org/newsletters/

6. https://www.wmda.info/

REFERENCES FOR TABLE 1 & 2 clinicaltrials.gov

More questions?

Call 1 (866) 606-2790 • E-mail info@insception.com • Visit insception.com